A method for predicting therapeutic effect of combination therapy with peginterferon and ribavirin in chronic hepatitis C therapy, comprising:a drug-sensitivity marker detection step of detecting a drug-sensitivity marker in a biological sample anda drug-sensitivity evaluation step of evaluating drug sensitivity of the biological sample on the basis of an expression level of the drug-sensitivity marker, whereinthe biological sample is a cell or tissue derived from liver, andthe drug-sensitivity marker comprises at least one microRNA selected from the group consisting of microRNAs shown in SEQ ID NOs: 1 to 37.
